What is the incidence rate of skin rash associated with Dolo (Paracetamol/Acetaminophen) 500mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Incidence of Skin Rash with Paracetamol (Dolo) 500mg

Skin rash from paracetamol (acetaminophen) is rare, occurring in well under 1% of patients, with severe cutaneous reactions being exceptionally uncommon. 1

Documented Incidence Rates

The FDA drug label for paracetamol warns that acetaminophen "may cause severe skin reactions" but does not provide a specific incidence rate, indicating these reactions are uncommon enough not to warrant precise quantification in routine use. 1 The label lists symptoms including skin reddening, blisters, and rash, with instructions to stop use immediately if a skin reaction occurs. 1

Evidence from Clinical Studies

Research data provides limited but informative incidence estimates:

  • Cross-reactivity studies in patients with NSAID-induced skin disorders found that approximately 19% of patients with aspirin-induced urticaria also reacted to acetaminophen, though this represents a highly selected population already predisposed to drug reactions. 2 This figure does not represent the general population risk.

  • Case reports document rare presentations including fixed drug eruption 3, 4 and cellulitis-like reactions 4, but these remain isolated case reports rather than systematic incidence data.

  • N-acetylcysteine treatment studies (the antidote for paracetamol overdose) showed 14% of Chinese patients developed skin rash, but this was attributed to the antidote itself rather than paracetamol. 5

Clinical Context and Risk Factors

The general population risk of paracetamol-induced rash is substantially lower than with other analgesics. For comparison:

  • NSAIDs like amprenavir show rash incidence ≤27% 6
  • Antiretroviral NNRTIs cause rash in the majority of cases 6
  • Tyrosine kinase inhibitors show rash rates of 11-43% depending on the agent 6

Risk factors for acetaminophen intolerance include:

  • History of aspirin-induced anaphylactoid reactions (RR = 5.7) 2
  • Aspirin intolerance (RR = 5.4) 2
  • Atopic status increases risk specifically for other NSAIDs but less clearly for acetaminophen 2

Severity Spectrum

When rash does occur with paracetamol:

  • Most reactions are mild with simple erythema or urticaria 1
  • Severe reactions are extremely rare, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and bullous fixed drug eruption 3, 4
  • Fixed drug eruption represents the most commonly reported pattern in case literature, recurring in the same anatomic location with re-exposure 3, 4

Critical Management Points

If skin reaction occurs:

  • Stop paracetamol immediately and permanently 1
  • Seek medical evaluation right away, particularly if accompanied by blistering, mucosal involvement, or systemic symptoms 1
  • Do not rechallenge with paracetamol if confirmed as causative agent 7

Common pitfall: Cellulitis-like presentations may be misdiagnosed as infection rather than drug reaction, leading to inappropriate antibiotic therapy and continued paracetamol exposure. 4

References

Research

Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999

Research

Acetaminophen-induced cellulitis-like fixed drug eruption.

Indian journal of dermatology, 2011

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Erythematous Flat Rash in HIV Patient on Antiretrovirals

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.